Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Regeneron Pharmaceuticals Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.22, while Regeneron Pharmaceuticals Inc trades at $796.76 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| NVDL | REGN | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $812.27 |
52-Week Low | $21.76 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.00, up 4.77% in the last 24 hours. The technical outlook is bullish, supported by moving averages, though the RSI suggests mild overbought conditions. Recent corporate actions include two stock splits effective June 2026. The fund provides leveraged exposure to NVIDIA, which remains a dominant force in AI, but key financial ratios for NVDL itself are not publicly detailed as it is an ETF tracking daily returns.
The outlook for NVDL hinges on NVIDIA's performance, with bullish technicals and media sentiment pointing to potential gains, especially around earnings. However, risks include high volatility from daily leverage reset, which can amplify losses during NVIDIA downturns, as seen in past sharp declines. Investors should weigh the leveraged structure's compounding effects against NVIDIA's strong AI-driven growth trajectory.
Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.
Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
